Pharming Group (PHGUF) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharming Group is set to acquire Abliva AB for approximately $66.1 million, enhancing its late-stage pipeline with Abliva’s promising KL1333, a treatment for mitochondrial diseases. The acquisition will be financed using existing cash reserves, with no external funding needed, and is expected to significantly impact Pharming’s growth. The deal has been unanimously supported by Abliva’s board and major shareholders, with regulatory approvals anticipated before the end of the acceptance period.
For further insights into PHGUF stock, check out TipRanks’ Stock Analysis page.
